Panel Back's Novo's Diabetes Combo, But Will The Market?
Executive Summary
An FDA advisory panel unanimously backed approval of Novo Nordisk AS' fixed-dose combination of Victoza (liraglutide) and Tresiba (insulin degludec), but if the agency approves the drug, it will be facing a market full of competitors and several other new products coming down the pike.
You may also be interested in...
Sanofi's 2-Pen Diabetes Combo Perplexes FDA
Sanofi SA's strategy of using two pen injectors for its fixed-ratio combination that combines its experimental glucagon-like peptide-1 receptor agonist lixisenatide with its US-approved diabetes drug Lantus (basal insulin glargine) has the FDA perplexed and concerned about the potential for adverse events and medication errors.
FDA On Novo's Diabetes Combo: It's Complicated
A May 24 advisory panel meeting is critical for Novo Nordisk's effort to convince the FDA to approve the Danish company's fixed-dose combination diabetes drug IDegLira – which unites Victoza (liraglutide) with Tresiba (insulin degludec) – but regulators questioned the firm's trial design.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.